We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dopamine and Norepinephrine in Shock Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00314704
Recruitment Status : Completed
First Posted : April 14, 2006
Last Update Posted : February 1, 2010
Information provided by:
Sepsis Occurrence in Acutely Ill Patients

Brief Summary:
The purpose of this study is to compare the efficacy of dopamine and norepinephrine, two commonly used vasopressor agents, in the treatment of shock.

Condition or disease Intervention/treatment Phase
Shock Drug: dopamine versus norepinephrine Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1679 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock
Study Start Date : December 2003
Actual Primary Completion Date : October 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Primary Outcome Measures :
  1. 28 day survival

Secondary Outcome Measures :
  1. ICU survival
  2. Hospital survival
  3. Severity of organ dysfunction in the ICU (SOFA score)
  4. Duration of ICU stay
  5. Time spent on vasopressors (vasopressor free days)
  6. Time spent on mechanical ventilation (ventilator free days)
  7. Time spent on renal replacement (renal replacement free days)
  8. Efficacy of dopamine to correct hypotension
  9. Hemodynamic effects
  10. Concomitant use of dobutamine or other inotropic agents
  11. Tolerance: arrhythmia (incidence of ventricular tachycardia, ventricular fibrillation and atrial fibrillation), myocardial necrosis, skin necrosis, limb or distal extremity ischemia.
  12. Occurrence of secondary infections
  13. Impact of target blood pressure on outcome

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mean arterial pressure less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading (in example with at least 1000 mL crystalloid or 500 ml colloid) unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated (e.g. CVP> 12 mmHg or PAOP > 14 mmHg).

Exclusion Criteria:

  • Serious arrhythmia such as rapid atrial fibrillation (> 160/min) or ventricular tachycardia.
  • Brain death.
  • Open label administration of dopamine, norepinephrine, epinephrine or phenylephrine for more than 4hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314704

Layout table for location information
University Hospital of Vienna
Vienna, Austria, 1090
CHU Saint Pierre
Brussels, Belgium, 1000
CHU Brugmann
Brussels, Belgium, 1020
HIS Ixelles
Brussels, Belgium, 1050
Erasme University Hospital
Brussels, Belgium, 1070
St Elisabeth
Brussels, Belgium, 1180
CHU Charleroi
Charleroi, Belgium, 6000
Hospital Universitario Rio Hortega
Valladolid, Spain, 47002
Sponsors and Collaborators
Sepsis Occurrence in Acutely Ill Patients
Layout table for investigator information
Principal Investigator: Daniel De Backer, MD, PhD SOAP investigators
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00314704    
Other Study ID Numbers: SOAP vasopressors
First Posted: April 14, 2006    Key Record Dates
Last Update Posted: February 1, 2010
Last Verified: April 2006
Keywords provided by Sepsis Occurrence in Acutely Ill Patients:
circulatory failure
septic shock
cardiogenic shock
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Cardiotonic Agents
Dopamine Agents
Protective Agents